日本語English简体中文 繁體中文

130A Veritas In Silico Inc.Veritas In SilicoTSE Growth / Pharmaceuticals

0 posts

Veritas In Silico Inc. stock hit limit-up on Nov 19: what happened

It closed at ¥365 on Nov 19 (+¥80.0, +28.07%), limit-up, ranking #5 among the top gainers of all stocks on the Tokyo Stock Exchange.

No disclosures were found for this stock around that day. Share what you know in the posts below.

Changes are calculated from the closing prices this site collects daily; limit-up/down is an estimate based on the daily price limit. Please make your own investment decisions.

Veritas In Silico Inc. (130A) at a glance

Code
130A
Company
Veritas In Silico Inc.
Local name
Veritas In Silico
Market
TSE Growth
Sector
Pharmaceuticals
Share price
¥365 +80.0 (+28.07%) Nov 19 close

Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.

Veritas In Silico Inc. (130A) Stock Price History

Veritas In Silico Inc. closed at ¥365 on Nov 19, 2026, +8.0% over 1 month, −27.7% over 1 year.

2026-10-29 第三者割当による第5回(行使価額修正条項付)及び第6回から第9回新株予約権(タ…2026-11-11 2026年12月期 第3四半期決算短信〔日本基準〕(非連結) / 2026 年12月期 通期業績予想の修正に関するお知らせ¥418¥225Oct 19Nov 19
Price5-day MA25-day MANikkei 225Disclosures
1-Month High¥418Oct 20
1-Month Low¥225Nov 17
1-Week Change+42.0%vs Nov 12
1-Month Change+8.0%vs Oct 19

If you had invested ¥100,000 1 month ago, it would be worth ¥107,988 today (+8.0%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved −8.4%, while this stock moved +8.0%.

Last 10 Trading Days

DateCloseChange% Change
Nov 19 (Thu)¥365+80+28.07%
Nov 18 (Wed)¥285+60+26.67%
Nov 17 (Tue)¥225−5−2.17%
Nov 16 (Mon)¥230−16−6.50%
Nov 13 (Fri)¥246−11−4.28%
Nov 12 (Thu)¥257+2+0.78%
Nov 11 (Wed)¥255−2−0.78%
Nov 10 (Tue)¥257+17+7.08%
Nov 9 (Mon)¥240−26−9.77%
Nov 6 (Fri)¥266−15−5.34%
2026-10-13 第三者割当による第5回(行使価額修正条項付)及び第6回から第9回新株予約権(タ…2026-10-29 第三者割当による第5回(行使価額修正条項付)及び第6回から第9回新株予約権(タ…2026-11-11 2026年12月期 第3四半期決算短信〔日本基準〕(非連結) / 2026 年12月期 通期業績予想の修正に関するお知らせ¥449¥225Aug 19Nov 19
Price5-day MA25-day MANikkei 225Disclosures
3-Month High¥449Aug 25
3-Month Low¥225Nov 17
1-Month Change+8.0%vs Oct 19
3-Month Change−12.0%vs Aug 19

If you had invested ¥100,000 3 months ago, it would be worth ¥87,952 today (−12.0%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved −9.0%, while this stock moved −12.0%.

Last 10 Trading Days

DateCloseChange% Change
Nov 19 (Thu)¥365+80+28.07%
Nov 18 (Wed)¥285+60+26.67%
Nov 17 (Tue)¥225−5−2.17%
Nov 16 (Mon)¥230−16−6.50%
Nov 13 (Fri)¥246−11−4.28%
Nov 12 (Thu)¥257+2+0.78%
Nov 11 (Wed)¥255−2−0.78%
Nov 10 (Tue)¥257+17+7.08%
Nov 9 (Mon)¥240−26−9.77%
Nov 6 (Fri)¥266−15−5.34%
2026-10-13 第三者割当による第5回(行使価額修正条項付)及び第6回から第9回新株予約権(タ…2026-10-29 第三者割当による第5回(行使価額修正条項付)及び第6回から第9回新株予約権(タ…2026-11-11 2026年12月期 第3四半期決算短信〔日本基準〕(非連結) / 2026 年12月期 通期業績予想の修正に関するお知らせ¥449¥225May 19Nov 19
Price25-day MA75-day MANikkei 225Disclosures
6-Month High¥449Aug 25
6-Month Low¥225Nov 17
3-Month Change−12.0%vs Aug 19
6-Month Change−9.0%vs May 19

If you had invested ¥100,000 6 months ago, it would be worth ¥91,022 today (−9.0%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved −1.8%, while this stock moved −9.0%.

Monthly Closes

MonthMonth-End CloseMonthly %
Nov 2026¥365+21.3%
Oct 2026¥301−31.3%
Sep 2026¥438−1.8%
Aug 2026¥446+9.9%
Jul 2026¥406−5.8%
Jun 2026¥431+3.6%
May 2026¥416−8.2%
2026-10-13 第三者割当による第5回(行使価額修正条項付)及び第6回から第9回新株予約権(タ…2026-10-29 第三者割当による第5回(行使価額修正条項付)及び第6回から第9回新株予約権(タ…2026-11-11 2026年12月期 第3四半期決算短信〔日本基準〕(非連結) / 2026 年12月期 通期業績予想の修正に関するお知らせ¥610¥225Nov 19Nov 19
Price25-day MA75-day MANikkei 225Disclosures
52-Week High¥610Dec 24
52-Week Low¥225Nov 17
Year to Date−24.0%vs Dec 30
From 52-Week High−40.2%Dec 24

If you had invested ¥100,000 1 year ago, it would be worth ¥72,277 today (−27.7%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved +22.5%, while this stock moved −27.7%.

Monthly Closes

MonthMonth-End CloseMonthly %
Nov 2026¥365+21.3%
Oct 2026¥301−31.3%
Sep 2026¥438−1.8%
Aug 2026¥446+9.9%
Jul 2026¥406−5.8%
Jun 2026¥431+3.6%
May 2026¥416−8.2%
Apr 2026¥453−0.9%
Mar 2026¥457−7.5%
Feb 2026¥494+0.2%
Jan 2026¥493+2.7%
Dec 2025¥480−6.8%
Nov 2025¥515―
¥3,005¥246Feb 5, 2024Nov 19, 2026
Price13-week MA26-week MANikkei 225
3-Year High¥3,005Feb 5, 2024
3-Year Low¥246Nov 13, 2026
Annualized Return−53.1%
Max Drawdown−91.8%

If you had invested ¥100,000 3 years ago, it would be worth ¥12,146 today (−87.9%).Price change only; dividends and fees are not included.

Over the same period the Nikkei 225 moved +61.1%, while this stock moved −87.9%.

Yearly Closes

YearYear-End CloseYearly %
2026 (YTD)¥365−24.0%
2025¥480―

Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Feb 2024). Please check the latest prices before trading.

Veritas In Silico Inc. (130A) financial indicators

PBR
1.86
ROE
-55.14%
Dividend yield
0.00%

See all financial indicators for Veritas In Silico Inc. (market cap, DOE, equity ratio, EV, EBITDA, ROIC and more)

PER, ROE and dividend yield are based on company forecasts, calculated from earnings reports and the closing price after each trading day.

Key features of Veritas In Silico Inc. (130A)

Business overview

The company is a drug discovery venture that uses AI-driven drug discovery to create medicines targeting messenger RNA (mRNA). It has upgraded its own drug discovery platform ibVIS, which combines informatics with experimental techniques, into aibVIS, which incorporates multiple AI systems and enables more efficient mRNA-targeted drug discovery. Small-molecule drug discovery targeting mRNA is a new approach that can address a range of diseases that were hard to target with conventional protein-targeting methods. Its business has two parts: a platform model, in which it conducts drug discovery research on mRNA-targeted small-molecule drugs jointly with several pharmaceutical companies, and a pipeline model, in which it holds its own pipeline, currently researching nucleic acid drugs mainly for rare diseases.

Summarized from the annual securities report (fiscal year ended December 2025) filed on EDINET.

Position within Pharmaceuticals (79 companies)

PBR1.86xBelow the sector median of 1.87x (No. 38 from the lowest)
ROE-55.14%No. 46 in the sector (highest first); median 4.17%
Market cap¥2.4 bnNo. 75 in the sector (largest first)

Ranks among stocks in the same Tokyo Stock Exchange sector (33 sectors). PER and PBR of zero or below (losses, negative equity) are excluded and ranked from the lowest.

Price milestones

52-week high¥6102025/12/24
52-week low¥22511/17
Current position36.4%Where the low is 0% and the high is 100% (close on 11/19: ¥365)
Year to date-24.0%No. 49 of 77 in the sector (best first)
1 year-27.7%

Based on closing prices (adjusted for stock splits, excluding dividends).

Kabutaro's ranking history

Top 50 gainers3 timesLatest: 11/19 (No. 5)
Top 50 losers5 timesLatest: 11/9 (No. 10)

Gainers and losers have been recorded since 9/2026.

Calculated as of 2026/11/19 17:30 JST. Updated every business day in the evening.

Recent disclosures (TDnet, in Japanese)

Show 1 more

Filings from the past 12 months (11).

Posts

This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.

No posts yet. Be the first to write something.

Write on the Veritas In Silico Inc. board

You will need this to delete your post. Please keep it safe.
By posting you agree to the board rules (Japanese). You are responsible for what you write.

More Japanese stocks in English

Japanese Stock Message Board: stocks available in English

Other boards in English